{"id":41885,"date":"2023-03-18T18:37:37","date_gmt":"2023-03-18T22:37:37","guid":{"rendered":"https:\/\/www.sisinternational.com\/?page_id=41885"},"modified":"2026-05-05T16:35:35","modified_gmt":"2026-05-05T20:35:35","slug":"etude-de-marche-sur-les-medicaments-orphelins","status":"publish","type":"page","link":"https:\/\/www.sisinternational.com\/fr\/competence\/etude-de-marche-sur-les-medicaments-orphelins\/","title":{"rendered":"Orphan Drug Market Research: A Sponsor&#8217;s Playbook"},"content":{"rendered":"<div class=\"sis-hero-preserved sis-injected-hero\" data-sis-injected=\"hero\">\n<h1 class=\"wp-block-heading\">\u00c9tude de march\u00e9 sur les m\u00e9dicaments orphelins<\/h1>\n<figure class=\"gb-block-image gb-block-image-e7ba8c3f\"><img loading=\"lazy\" decoding=\"async\" width=\"1456\" height=\"816\" class=\"gb-image gb-image-e7ba8c3f\" src=\"https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/08\/Nutritional-supplement-8.jpg\" alt=\"\u00c9tudes de march\u00e9 et strat\u00e9gie internationales SIS\" title=\"Nutritional supplement (8)\" srcset=\"https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/08\/Nutritional-supplement-8.jpg 1456w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/08\/Nutritional-supplement-8-300x168.jpg 300w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/08\/Nutritional-supplement-8-1024x574.jpg 1024w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/08\/Nutritional-supplement-8-768x430.jpg 768w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/08\/Nutritional-supplement-8-18x10.jpg 18w\" sizes=\"auto, (max-width: 1456px) 100vw, 1456px\"><\/figure>\n<\/p>\n<h2 class=\"wp-block-heading\">Qu\u2019est-ce qu\u2019un m\u00e9dicament orphelin ?<\/h2>\n<p>Les m\u00e9dicaments orphelins diagnostiquent, pr\u00e9viennent et traitent les maladies orphelines. Une maladie orpheline est une maladie ou une affection rare. Une telle maladie touche moins de 200 000 personnes aux \u00c9tats-Unis. Les maladies orphelines sont souvent graves, voire mortelles. En fait, le gouvernement am\u00e9ricain a adopt\u00e9 une loi appel\u00e9e Orphan Drug Act en 1983. Cette loi favorise la fabrication de m\u00e9dicaments orphelins s\u00fbrs et efficaces. Il accorde aux soci\u00e9t\u00e9s pharmaceutiques certains avantages financiers pour leurs travaux sur ces m\u00e9dicaments.<\/p>\n<p>La FDA fait de la recherche sur les maladies rares une priorit\u00e9. Ainsi, il soutient la recherche et le d\u00e9veloppement de nouveaux traitements contre les maladies rares. Un autre point cl\u00e9 est que le fait d\u2019avoir le statut de m\u00e9dicament orphelin permet aux sponsors de b\u00e9n\u00e9ficier d\u2019incitations, notamment\u00a0:<\/p>\n<ul class=\"wp-block-list\">\n<li>Exon\u00e9ration des frais d&#039;utilisation<\/li>\n<li>Cr\u00e9dits d&#039;imp\u00f4t pour essais cliniques qualifi\u00e9s<\/li>\n<li>Potentiel sept ans de droits de commercialisation exclusifs apr\u00e8s l&#039;approbation<\/li>\n<\/ul>\n<\/div>\n<h1>Orphan Drug Market Research: How Leading Sponsors Build Defensible Rare Disease Franchises<\/h1>\n<p>Rare disease economics reward sponsors who understand patients before they understand pricing. Orphan drug market research is the discipline that produces that understanding, and it has matured into one of the highest-leverage investments in pharmaceutical strategy.<\/p>\n<p>The economics are unusual. Patient populations are small, sometimes fewer than 5,000 globally, but treatment durations are long and willingness to pay is structural. A well-evidenced launch in Pompe, hereditary angioedema, or transthyretin amyloidosis can sustain a franchise for two decades. The work that separates a successful launch from an underperforming one happens years before approval, in the design of the evidence package and the mapping of the prescriber and payer ecosystem.<\/p>\n<h2>Why Orphan Drug Market Research Demands a Different Playbook<\/h2>\n<p>Conventional pharmaceutical research assumes accessible HCP panels, established treatment algorithms, and identifiable patient cohorts. Rare disease violates all three assumptions. A condition like Niemann-Pick Type C may have fewer than 100 active prescribers across the United States and Europe combined. Standard quantitative methods collapse at that sample size.<\/p>\n<p>The leading sponsors compensate with depth. They build KOL maps that distinguish between diagnosing physicians, treating physicians, and the small group of investigators who shape the literature. They invest in patient advocacy organization relationships years before Phase III readout. They construct payer value stories around natural history data because randomized comparators rarely exist.<\/p>\n<p><span style=\"color:#216896;border-left:3px solid #216896;padding-left:0.5rem;\">SIS International Research has observed that sponsors who commission structured B2B expert interviews with 25 to 40 specialists across academic medical centers, community practice, and patient advocacy leadership during Phase II consistently produce sharper indication prioritization decisions than those who wait for Phase III data.<\/span> The interviews surface diagnostic odyssey patterns, off-label competitive activity, and payer evidence gaps that quantitative work cannot detect.<\/p>\n<h2>The Evidence Architecture That Drives Market Access<\/h2>\n<p>HTA bodies in England (NICE), Germany (G-BA), France (HAS), and Canada (CADTH) each apply distinct frameworks to orphan products. NICE&#8217;s highly specialized technologies pathway accepts higher ICERs but demands specific evidence on disease severity and unmet need. Germany&#8217;s AMNOG process for orphan drugs grants automatic additional benefit below a revenue threshold, then resets at full dossier review.<\/p>\n<p>The sponsors who clear these gates early treat the payer value story as a research output, not a marketing deliverable. They commission HTA submission evidence work in parallel with Phase II, mapping which endpoints carry weight in each jurisdiction. Real-world evidence from natural history registries, patient-reported outcome instruments validated for the specific condition, and indirect treatment comparisons against standard of care all enter the evidence package before pivotal data lock.<\/p>\n<p>BioMarin&#8217;s approach with Voxzogo in achondroplasia and Alnylam&#8217;s sequencing of Onpattro, Givlaari, and Amvuttra illustrate the discipline. Each launch reused infrastructure, prescriber relationships, and payer dialogue from the prior program. The franchise compounds.<\/p>\n<h3>Diagnostic Odyssey Mapping as Commercial Intelligence<\/h3>\n<p>The average rare disease patient sees seven physicians over five years before diagnosis. That diagnostic odyssey is not just a clinical problem. It is the commercial map. Each touchpoint represents a prescriber who may suspect the condition but lacks the genetic testing pathway, the referral network, or the awareness to confirm it.<\/p>\n<p>Patient journey mapping in orphan drug market research traces these touchpoints with the patient and the caregiver, then validates them against claims data and physician interviews. The output identifies the specific specialists, often not the eventual treaters, who gate diagnosis. Companion diagnostic strategy, medical education investment, and field medical deployment all key off this map.<\/p>\n<h2>Indication Prioritization When Every Decision Is Capital-Intensive<\/h2>\n<p>Most rare disease assets have multiple potential indications. A gene therapy platform may address three conditions; a small molecule may have rationale across five. Sequencing matters because each indication consumes regulatory attention, manufacturing capacity, and commercial bandwidth.<\/p>\n<p>The framework that the strongest sponsors apply weighs four variables: addressable patient population at steady state, regulatory pathway certainty, payer precedent in the indication, and competitive density. <span style=\"color:#216896;border-left:3px solid #216896;padding-left:0.5rem;\">Across SIS International Research engagements with rare disease sponsors, indications scoring high on regulatory certainty and payer precedent but moderate on population frequently outperform larger indications with crowded competitive fields, because launch sequencing benefits from clean precedent more than scale.<\/span><\/p>\n<figure class=\"wp-block-table sis-injected-table\" data-sis-injected=\"table\">\n<table>\n<thead>\n<tr>\n<th>Variable<\/th>\n<th>What It Measures<\/th>\n<th>Common Source of Error<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Addressable population<\/td>\n<td>Diagnosed and diagnosable prevalence at launch<\/td>\n<td>Confusing epidemiologic prevalence with diagnosed prevalence<\/td>\n<\/tr>\n<tr>\n<td>Regulatory pathway<\/td>\n<td>Precedent for endpoint acceptance and accelerated approval<\/td>\n<td>Assuming FDA precedent transfers to EMA<\/td>\n<\/tr>\n<tr>\n<td>Payer precedent<\/td>\n<td>Reimbursed analogs at comparable price points<\/td>\n<td>Treating list price as net price<\/td>\n<\/tr>\n<tr>\n<td>Competitive density<\/td>\n<td>Pipeline assets within three years of approval<\/td>\n<td>Missing platform competitors from outside the therapeutic area<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n<p style=\"font-size:11px;color:#666;margin-top:4px;\"><em>Source: SIS International Research<\/em><\/p>\n<h2>Competitive Intelligence in Sparse Pipelines<\/h2>\n<p>Rare disease competitive intelligence rewards primary research over database subscriptions. ClinicalTrials.gov captures registered studies, but it misses the academic investigators running natural history work that signals future commercial entry. It misses platform companies, particularly in gene therapy and antisense, that can pivot to a new indication within 18 months.<\/p>\n<p>Structured expert interviews with academic investigators, conference intelligence from podium discussions at WORLDSymposium and ASGCT, and patent landscape analysis on capsid and delivery technology produce a more accurate forward view. Sponsors who commission this work quarterly catch competitive entries two to three years earlier than those relying on commercial databases alone.<\/p>\n<h2>Pricing and Access Research Before Phase III<\/h2>\n<p>Orphan pricing research starts with payer archetype interviews across at least five major markets. The questions concern budget impact thresholds, managed entry agreement appetite, outcomes-based contract feasibility, and the specific evidence that would move an HTA recommendation from restricted to broad use. Sponsors learn what pricing range is defensible, what evidence closes the gap, and which markets sequence first based on price reference effects.<\/p>\n<p>The mistake to avoid is treating pricing research as a late-stage exercise. Once Phase III protocols lock, the comparator, the endpoint, and the patient subgroup are fixed. Pricing flexibility is fixed with them.<\/p>\n<h2>Where the Discipline Is Heading<\/h2>\n<figure class=\"wp-block-image size-large sis-injected-img\" data-sis-injected=\"img\"><img loading=\"lazy\" decoding=\"async\" width=\"1456\" height=\"816\" class=\"gb-image gb-image-0303615c\" src=\"https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/08\/Nutritional-supplement-6.jpg\" alt=\"\u00c9tudes de march\u00e9 et strat\u00e9gie internationales SIS\" title=\"Nutritional supplement (6)\" srcset=\"https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/08\/Nutritional-supplement-6.jpg 1456w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/08\/Nutritional-supplement-6-300x168.jpg 300w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/08\/Nutritional-supplement-6-1024x574.jpg 1024w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/08\/Nutritional-supplement-6-768x430.jpg 768w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/08\/Nutritional-supplement-6-18x10.jpg 18w\" sizes=\"auto, (max-width: 1456px) 100vw, 1456px\"><\/figure>\n<p>Three shifts are reshaping orphan drug market research. First, gene therapy and one-time treatments are forcing payer dialogue to address durability evidence and long-term safety registries before launch, not after. Second, AI-enabled diagnostic tools are compressing the diagnostic odyssey in conditions like cardiac amyloidosis and Fabry disease, expanding addressable populations faster than historical models predict. Third, China and Brazil are becoming meaningful rare disease markets, requiring evidence packages adapted to local HTA logic rather than translated from Western dossiers.<\/p>\n<p>Sponsors who treat orphan drug market research as a continuous intelligence function, refreshed at each clinical milestone, build franchises that compound. Those who commission it as a one-time launch input leave value on the table.<\/p>\n<h2 id=\"about-sis-international\" style=\"font-family:Arial,sans-serif;color:#1a3d68;\">\u00c0 propos de SIS International<\/h2>\n<p><a href=\"https:\/\/www.sisinternational.com\/fr\/\">SIS International<\/a> propose des recherches quantitatives, qualitatives et strat\u00e9giques. Nous fournissons des donn\u00e9es, des outils, des strat\u00e9gies, des rapports et des informations pour la prise de d\u00e9cision. Nous menons \u00e9galement des entretiens, des enqu\u00eates, des groupes de discussion et d\u2019autres m\u00e9thodes et approches d\u2019\u00e9tudes de march\u00e9. <a href=\"https:\/\/www.sisinternational.com\/fr\/a-propos-de-la-recherche-internationale-sis\/contact-sis-international-market-research\/\">Contactez nous<\/a> pour votre prochain projet d&#039;\u00e9tude de march\u00e9.<\/p>\n<p><!-- sis-hreflang-start -->\n<link rel=\"alternate\" hreflang=\"en-US\" href=\"https:\/\/www.sisinternational.com\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"ar\" href=\"https:\/\/www.sisinternational.com\/ar\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"zh-CN\" href=\"https:\/\/www.sisinternational.com\/zh\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"zh-HK\" href=\"https:\/\/www.sisinternational.com\/zh_hk\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"nl-NL\" href=\"https:\/\/www.sisinternational.com\/nl\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"fr-FR\" href=\"https:\/\/www.sisinternational.com\/fr\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"de-DE\" href=\"https:\/\/www.sisinternational.com\/de\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"it-IT\" href=\"https:\/\/www.sisinternational.com\/it\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"ja\" href=\"https:\/\/www.sisinternational.com\/ja\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"ko-KR\" href=\"https:\/\/www.sisinternational.com\/ko\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"pl-PL\" href=\"https:\/\/www.sisinternational.com\/pl\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"pt-BR\" href=\"https:\/\/www.sisinternational.com\/pt\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"es-ES\" href=\"https:\/\/www.sisinternational.com\/es\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"en\" href=\"https:\/\/www.sisinternational.com\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"zh\" href=\"https:\/\/www.sisinternational.com\/zh\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"nl\" href=\"https:\/\/www.sisinternational.com\/nl\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"fr\" href=\"https:\/\/www.sisinternational.com\/fr\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"de\" href=\"https:\/\/www.sisinternational.com\/de\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"it\" href=\"https:\/\/www.sisinternational.com\/it\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"ko\" href=\"https:\/\/www.sisinternational.com\/ko\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"pl\" href=\"https:\/\/www.sisinternational.com\/pl\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"pt\" href=\"https:\/\/www.sisinternational.com\/pt\/expertise\/orphan-drug-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"es\" href=\"https:\/\/www.sisinternational.com\/es\/expertise\/orphan-drug-market-research\/\" \/>\n<!-- sis-hreflang-end --><\/p>\n<section class=\"sis-related-recovered\" data-sis-recovered-section=\"1\">\n<h3>Related SIS Resources<\/h3>\n<ul>\n<li><a href=\"https:\/\/www.sisinternational.com\/fr\/couverture\/les-ameriques\/etude-de-marche-dans-les-caraibes\/etude-de-marche-montserrat\/\" class=\"sis-link-recovered\">Research serves the Orphan Drug market<\/a><\/li>\n<li><a href=\"https:\/\/www.sisinternational.com\/fr\/solutions\/solutions-de-recherche-qualitative-et-quantitative\/\" class=\"sis-link-recovered\">\u00c9tude de march\u00e9 quantitative<\/a><\/li>\n<li><a href=\"https:\/\/www.sisinternational.com\/fr\/couverture\/les-ameriques\/etude-de-marche-en-amerique-latine\/etude-de-marche-a-rio-de-janeiro\/\" class=\"sis-link-recovered\">Recherche d&#039;entr\u00e9e sur le march\u00e9<\/a><\/li>\n<li><a href=\"https:\/\/www.sisinternational.com\/fr\/couverture\/etude-de-marche-en-asie\/etude-de-marche-krong-siem-reap\/\" class=\"sis-link-recovered\">Recherche d&#039;entr\u00e9e sur le march\u00e9<\/a><\/li>\n<\/ul>\n<\/section>","protected":false},"excerpt":{"rendered":"<p>La recherche sur le march\u00e9 des m\u00e9dicaments orphelins aide les soci\u00e9t\u00e9s pharmaceutiques \u00e0 d\u00e9couvrir les besoins des patients et \u00e0 g\u00e9n\u00e9rer des id\u00e9es pour am\u00e9liorer les produits et d\u00e9velopper ceux existants.<\/p>","protected":false},"author":1,"featured_media":64093,"parent":14514,"menu_order":218,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-41885","page","type-page","status-publish","has-post-thumbnail"],"_links":{"self":[{"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/pages\/41885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/comments?post=41885"}],"version-history":[{"count":9,"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/pages\/41885\/revisions"}],"predecessor-version":[{"id":87794,"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/pages\/41885\/revisions\/87794"}],"up":[{"embeddable":true,"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/pages\/14514"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/media\/64093"}],"wp:attachment":[{"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/media?parent=41885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}